{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T22:46:52Z","timestamp":1787957212758,"version":"build-2784847793"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2016,11,28]],"date-time":"2016-11-28T00:00:00Z","timestamp":1480291200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2017,5]]},"DOI":"10.1245\/s10434-016-5707-0","type":"journal-article","created":{"date-parts":[[2016,11,28]],"date-time":"2016-11-28T15:09:22Z","timestamp":1480345762000},"page":"1406-1413","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":47,"title":["Analysis of Predictors of Resection and Survival in Locally Advanced Stage III Pancreatic Cancer: Does the Nature of Chemotherapy Regimen Influence Outcomes?"],"prefix":"10.1245","volume":"24","author":[{"given":"Filip","family":"Bednar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mazen S.","family":"Zenati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Steve","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon","family":"Winters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lee M.","family":"Ocuin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan","family":"Bahary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa E.","family":"Hogg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"III","given":"Herbert J.","family":"Zeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amer H.","family":"Zureikat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,11,28]]},"reference":[{"issue":"16","key":"5707_CR1","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1200\/JCO.2014.59.7930","volume":"33","author":"GM Heestand","year":"2015","unstructured":"Heestand GM, Murphy JD, Lowy AM. Approach to patients with pancreatic cancer without detectable metastases. J Clin Oncol. 2015;33(16):1770\u20138. doi:\n                    10.1200\/JCO.2014.59.7930\n                    \n                  .","journal-title":"J Clin Oncol"},{"issue":"31","key":"5707_CR2","doi-asserted-by":"publisher","first-page":"4105","DOI":"10.1200\/JCO.2011.34.8904","volume":"29","author":"PJ Loehrer","year":"2011","unstructured":"Loehrer PJ, Feng Y, Cardenes H, et al. Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: an Eastern Cooperative Oncology Group trial. J Clin Oncol. 2011;29(31):4105\u201312. doi:\n                    10.1200\/JCO.2011.34.8904\n                    \n                  .","journal-title":"J Clin Oncol"},{"issue":"9","key":"5707_CR3","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.1093\/annonc\/mdn281","volume":"19","author":"B Chauffert","year":"2008","unstructured":"Chauffert B, Mornex F, Bonnetain F, et al. Phase III trial comparing intensive induction chemoradiotherapy (60\u00a0Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2. Ann Oncol. 2008;19(9):1592\u20139. doi:\n                    10.1093\/annonc\/mdn281\n                    \n                  .","journal-title":"Ann Oncol."},{"key":"5707_CR4","doi-asserted-by":"crossref","unstructured":"Hammel P, Huguet F, Van Laethem J-L, et al. Comparison of chemoradiotherapy (CRT) and chemotherapy (CT) in patients with a locally advanced pancreatic cancer (LAPC) controlled after 4\u00a0months of gemcitabine with or without erlotinib: Final results of the international phase III LAP 07 study. ASCO Meet Abstr. 2013;31(15_suppl):LBA4003. \n                    http:\/\/hwmaint.meeting.ascopubs.org\/cgi\/content\/abstract\/31\/15_suppl\/LBA4003\n                    \n                  . Accessed 28 Mar 2016.","DOI":"10.1200\/jco.2013.31.18_suppl.lba4003"},{"issue":"4","key":"5707_CR5","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/S1470-2045(13)70021-4","volume":"14","author":"S Mukherjee","year":"2013","unstructured":"Mukherjee S, Hurt CN, Bridgewater J, et al. Gemcitabine-based or capecitabine-based chemoradiotherapy for locally advanced pancreatic cancer (SCALOP): a multicentre, randomised, phase 2 trial. Lancet Oncol. 2013;14(4):317\u201326. doi:\n                    10.1016\/S1470-2045(13)70021-4\n                    \n                  .","journal-title":"Lancet Oncol."},{"issue":"3","key":"5707_CR6","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1200\/JCO.2006.07.5663","volume":"25","author":"F Huguet","year":"2007","unstructured":"Huguet F, Andr\u00e9 T, Hammel P, et al. Impact of chemoradiotherapy after disease control with chemotherapy in locally advanced pancreatic adenocarcinoma in GERCOR phase II and III studies. J Clin Oncol. 2007;25(3):326\u201331. doi:\n                    10.1200\/JCO.2006.07.5663\n                    \n                  .","journal-title":"J Clin Oncol."},{"key":"5707_CR7","doi-asserted-by":"publisher","first-page":"2403","DOI":"10.1200\/JCO.1997.15.6.2403","volume":"15","author":"HA Burris 3rd","year":"1997","unstructured":"Burris HA 3rd, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997;15:2403\u201313.","journal-title":"J Clin Oncol."},{"issue":"3","key":"5707_CR8","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1200\/JCO.1985.3.3.373","volume":"3","author":"DJ Klaassen","year":"1985","unstructured":"Klaassen DJ, MacIntyre JM, Catton GE, Engstrom PF, Moertel CG. Treatment of locally unresectable cancer of the stomach and pancreas: a randomized comparison of 5-fluorouracil alone with radiation plus concurrent and maintenance 5-fluorouracil\u2013an Eastern Cooperative Oncology Group study. J Clin Oncol. 1985;3(3):373\u20138.","journal-title":"J Clin Oncol."},{"issue":"3","key":"5707_CR9","first-page":"164","volume":"32","author":"JJ Hazel","year":"1981","unstructured":"Hazel JJ, Thirlwell MP, Huggins M, Maksymiuk A, MacFarlane JK. Multi-drug chemotherapy with and without radiation for carcinoma of the stomach and pancreas: a prospective randomized trial. J Can Assoc Radiol. 1981;32(3):164\u20135.","journal-title":"J Can Assoc Radiol."},{"key":"5707_CR10","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1245\/s10434-009-0408-6","volume":"16","author":"MP Callery","year":"2009","unstructured":"Callery MP, Chang KJ, Fishman EK, Talamonti MS, William Traverso L, Linehan DC. Pretreatment assessment of resectable and borderline resectable pancreatic cancer: expert consensus statement. Ann Surg Oncol. 2009;16:1727\u201333.","journal-title":"Ann Surg Oncol."},{"key":"5707_CR11","unstructured":"NCCN guidelines version2.2015.\n                    https:\/\/www.nccn.org\/\/professionals\/physician_gls\/pdf\/pancreatic\n                    \n                  ."},{"issue":"19","key":"5707_CR12","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","volume":"364","author":"T Conroy","year":"2011","unstructured":"Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364(19):1817\u201325. doi:\n                    10.1056\/NEJMoa1011923\n                    \n                  .","journal-title":"N Engl J Med."},{"issue":"18","key":"5707_CR13","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","volume":"369","author":"DD Hoff Von","year":"2013","unstructured":"Von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369(18):1691\u2013703. doi:\n                    10.1056\/NEJMoa1304369\n                    \n                  .","journal-title":"N Engl J Med."},{"issue":"4","key":"5707_CR14","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1002\/jso.23392","volume":"108","author":"BA Boone","year":"2013","unstructured":"Boone BA, Steve J, Krasinskas AM, et al. Outcomes with FOLFIRINOX for borderline resectable and locally unresectable pancreatic cancer. J Surg Oncol. 2013;108(4):236\u201341. doi:\n                    10.1002\/jso.23392\n                    \n                  .","journal-title":"J Surg Oncol."},{"issue":"1","key":"5707_CR15","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1186\/1471-2407-12-199","volume":"12","author":"PJ Hosein","year":"2012","unstructured":"Hosein PJ, Macintyre J, Kawamura C, et al. A retrospective study of neoadjuvant FOLFIRINOX in unresectable or borderline-resectable locally advanced pancreatic adenocarcinoma. BMC Cancer. 2012;12(1):199. doi:\n                    10.1186\/1471-2407-12-199\n                    \n                  .","journal-title":"BMC Cancer."},{"issue":"1","key":"5707_CR16","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1007\/s12032-012-0361-2","volume":"30","author":"KS Gunturu","year":"2013","unstructured":"Gunturu KS, Yao X, Cong X, et al. FOLFIRINOX for locally advanced and metastatic pancreatic cancer: single institution retrospective review of efficacy and toxicity. Med Oncol. 2013;30(1):361. doi:\n                    10.1007\/s12032-012-0361-2\n                    \n                  .","journal-title":"Med Oncol."},{"issue":"8","key":"5707_CR17","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1097\/MPA.0b013e31829e2006","volume":"42","author":"H Mahaseth","year":"2013","unstructured":"Mahaseth H, Brutcher E, Kauh J, et al. Modified FOLFIRINOX regimen with improved safety and maintained efficacy in pancreatic adenocarcinoma. Pancreas. 2013;42(8):1311\u20135. doi:\n                    10.1097\/MPA.0b013e31829e2006\n                    \n                  .","journal-title":"Pancreas."},{"issue":"5","key":"5707_CR18","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1634\/theoncologist.2012-0435","volume":"18","author":"JE Faris","year":"2013","unstructured":"Faris JE, Blaszkowsky LS, McDermott S, et al. FOLFIRINOX in locally advanced pancreatic cancer: the Massachusetts General Hospital Cancer Center experience. Oncologist. 2013;18(5):543\u20138. doi:\n                    10.1634\/theoncologist.2012-0435\n                    \n                  .","journal-title":"Oncologist."},{"issue":"4","key":"5707_CR19","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/j.clcc.2014.09.005","volume":"13","author":"SY Moorcraft","year":"2014","unstructured":"Moorcraft SY, Khan K, Peckitt C, et al. FOLFIRINOX for locally advanced or metastatic pancreatic ductal adenocarcinoma: the Royal Marsden experience. Clin Colorectal Cancer. 2014;13(4):232\u20138. doi:\n                    10.1016\/j.clcc.2014.09.005\n                    \n                  .","journal-title":"Clin Colorectal Cancer."},{"issue":"1","key":"5707_CR20","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1245\/s10434-014-3898-9","volume":"22","author":"L Marthey","year":"2015","unstructured":"Marthey L, Sa-Cunha A, Blanc JF, et al. FOLFIRINOX for locally advanced pancreatic adenocarcinoma: results of an AGEO multicenter prospective observational cohort. Ann Surg Oncol. 2015;22(1):295\u2013301. doi:\n                    10.1245\/s10434-014-3898-9\n                    \n                  .","journal-title":"Ann Surg Oncol."},{"issue":"11","key":"5707_CR21","doi-asserted-by":"publisher","first-page":"3512","DOI":"10.1245\/s10434-015-4647-4","volume":"22","author":"E Sadot","year":"2015","unstructured":"Sadot E, Doussot A, O\u2019Reilly EM, et al. FOLFIRINOX Induction Therapy for Stage 3 Pancreatic Adenocarcinoma. Ann Surg Oncol. 2015;22(11):3512\u201321. doi:\n                    10.1245\/s10434-015-4647-4\n                    \n                  .","journal-title":"Ann Surg Oncol."},{"issue":"4","key":"5707_CR22","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1245\/s10434-014-4225-1","volume":"22","author":"M Blazer","year":"2015","unstructured":"Blazer M, Wu C, Goldberg RM, et al. Neoadjuvant modified (m) FOLFIRINOX for locally advanced unresectable (LAPC) and borderline resectable (BRPC) adenocarcinoma of the pancreas. Ann Surg Oncol. 2015;22(4):1153\u20139. doi:\n                    10.1245\/s10434-014-4225-1\n                    \n                  .","journal-title":"Ann Surg Oncol."},{"issue":"1","key":"5707_CR23","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1097\/SLA.0000000000000867","volume":"261","author":"CR Ferrone","year":"2015","unstructured":"Ferrone CR, Marchegiani G, Hong TS, et al. Radiological and surgical implications of neoadjuvant treatment with FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer. Ann Surg. 2015;261(1):12\u20137. doi:\n                    10.1097\/SLA.0000000000000867\n                    \n                  .","journal-title":"Ann Surg."},{"issue":"6","key":"5707_CR24","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1016\/S1470-2045(16)00172-8","volume":"17","author":"M Suker","year":"2016","unstructured":"Suker\u00a0M, Beumer BR, Sadot E, Marthey L, Faris JE, Mellon EA, El-Rayes BF, et al. FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis. Lancet Oncol. 2016;17(6):801-10. doi:\n                    10.1016\/S1470-2045(16)00172-8\n                    \n                  .","journal-title":"Lancet Oncol."},{"issue":"23","key":"5707_CR25","doi-asserted-by":"publisher","first-page":"5749","DOI":"10.1002\/cncr.27636","volume":"118","author":"MH Katz","year":"2012","unstructured":"Katz\u00a0MH, Fleming JB, Bhosale P, Varadhachary G, Lee JE, Wolff R, et al. Response of borderline resectable pancreatic cancer to neoadjuvant therapy is not reflected by radiographic indicators. Cancer. 2012;118(23):5749-56. doi:\n                    10.1002\/cncr.27636\n                    \n                  .","journal-title":"Cancer."},{"issue":"13","key":"5707_CR26","doi-asserted-by":"publisher","first-page":"4351","DOI":"10.1245\/s10434-014-3842-z","volume":"21","author":"BA Boone","year":"2014","unstructured":"Boone\u00a0BA, Steve J, Zenati MS, et al. Serum CA 19-9 response to neoadjuvant therapy is associated with outcome in pancreatic adenocarcinoma. Ann Surg Oncol. 2014;21(13):4351\u20138. doi:\n                    10.1245\/s10434-014-3842-z\n                    \n                  .","journal-title":"Ann Surg Oncol."},{"issue":"7","key":"5707_CR27","doi-asserted-by":"publisher","first-page":"1794","DOI":"10.1245\/s10434-010-0943-1","volume":"17","author":"MH Katz","year":"2010","unstructured":"Katz MH, Varadhachary GR, Fleming JB, Wolff RA, Lee JE, Pisters PW, et al. Serum\u00a0CA 19-9\u00a0as a marker of resectability and survival in patients with potentially resectable pancreatic cancer treated with neoadjuvant chemoradiation. Ann Surg Oncol. 2010;17(7):1794\u2013801. doi:\n                    10.1245\/s10434-010-0943-1\n                    \n                  .","journal-title":"Ann Surg Oncol."},{"issue":"10","key":"5707_CR28","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1111\/hpb.12448","volume":"17","author":"M Aldakkak","year":"2015","unstructured":"Aldakkak M, Christians KK, Krepline AN, George B, Ritch PS, Erickson BA, et al. Pre-treatment carbohydrate\u00a0antigen\u00a019-9 does not predict the response to neoadjuvant therapy in patients with localized pancreatic cancer. HPB (Oxford). 2015;17(10):942-52. doi:\n                    10.1111\/hpb.12448\n                    \n                  .","journal-title":"HPB"},{"key":"5707_CR29","doi-asserted-by":"publisher","first-page":"2352","DOI":"10.1245\/s10434-014-4274-5","volume":"22","author":"S Moningi","year":"2015","unstructured":"Moningi S, Dholakia AS, Raman SP, et al: The Role of stereotactic body radiation therapy for pancreatic cancer: a single-institution experience. Ann Surg Oncol. 2015;22:2352\u20138.","journal-title":"Ann Surg Oncol."},{"issue":"22","key":"5707_CR30","doi-asserted-by":"publisher","first-page":"2654","DOI":"10.1200\/JCO.2016.67.5561","volume":"34","author":"EP Balaban","year":"2016","unstructured":"Balaban EP, Mangu PB, Khorana AA, et al. Locally advanced unresectable pancreatic cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2016;34(22):2654\u201368.","journal-title":"J Clin Oncol."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-016-5707-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1245\/s10434-016-5707-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-016-5707-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,17]],"date-time":"2020-02-17T22:13:55Z","timestamp":1581977635000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1245\/s10434-016-5707-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11,28]]},"references-count":30,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017,5]]}},"alternative-id":["5707"],"URL":"https:\/\/doi.org\/10.1245\/s10434-016-5707-0","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,11,28]]},"assertion":[{"value":"6 August 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 November 2016","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}